Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 231

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy

Open access
Shi, Xiaojing, Cheng, Qinqin, Hou, Tianling, Han, Menglu, Smbatyan, Goar, Lang, Julie E., Epstein, Alan L., Lenz, Heinz-Josef, Zhang, Yong · 2020 · Molecular Therapy

Abstract

Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their unique and pharmacologically important properties, cell-derived exosome nanoparticles have drawn significant interest for drug development. By genetically modifying exosomes with two distinct types of surface-displayed monoclonal antibodies, we have developed an exosome platform termed synthetic multivalent antibodies retargeted exosome (SMART-Exo) for controlling cellular immunity. Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors. By redirecting and activating cytotoxic T cells toward attacking HER2-expressing breast cancer cells, the designed SMART-Exos exhibited highly potent and specific anti-tumor activity both in vitro and in vivo. This work demonstrates preclinical feasibility of utilizing endogenous exosomes for targeted breast cancer immunotherapy and the SMART-Exos as a broadly applicable platform technology for the development of next-generation immuno-nanomedicines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2019.11.020

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 231

Metadata

Authors
Shi, X., Cheng, Q., Hou, T., Han, M., Smbatyan, G., Lang, J. E., Epstein, A. L., Lenz, H.-J., & Zhang, Y.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2020-02
Volume
28
Issue
2
Pages
536-547
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2989988576
Cited by
231
References
8
FWCI
6.09
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. https://app.cochat.ai/papers/10.1016/j.ymthe.2019.11.020
The paper
Shi, X., Cheng, Q., Hou, T., Han, M., Smbatyan, G., Lang, J. E., Epstein, A. L., Lenz, H.-J., & Zhang, Y. (2020). Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2019.11.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.